Replies to post #2355 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

Paxlovid does not work in standard risk patients.

Good to see you have moved on to a different meaningless approach.

What do you mean by Paxlovid doesn't work in standard risk patients?

Do you know that Paxlovid has massive sales in the elderly and in treating high risk patients?

[willyw]

Paxlovid does not work in standard risk patients. Check your data. EDP-235 won’t work either.

Ask yourself; what is the bar to approval?
According to you it seems to be incredibly low if Paxlovid doesn't work.

https://www.globaldata.com/media/pharma/top-selling-covid-19-drug-paxlovid-see-sales-decrease-2023-following-second-booster-says-globaldata/

"Although many pharmaceutical companies have launched therapeutic drugs for COVID-19, Pfizer’s Paxlovid takes the top spot as market leader. The drug has expected peak sales of $30.7 billion in 2022 and total generated sales of $81 billion between 2021 and 2028, according to GlobalData, a leading data and analytics company."

So..... if Enanta's compound were better, more efficacious, once a day without boosting it would seem approval would be simple since the bar is so incredibly low.